Benitec Biopharma reports FY2023 net loss of $19.6M; FDA cleared BB-301 IND; completed $30.9M offering

Benitec Biopharma Inc.

Net loss $19.6M ($14.12/share) vs $18.2M ($37.88/share) prior year; cash $2.5M at June 30, 2023.
FDA cleared IND for BB-301 for OPMD in June 2023; 15 subjects enrolled in Natural History Study as of September.
Closed $30.9M public offering in August 2023 to fund BB-301 clinical development and operations.
R&D expenses $12.8M (up from $11.3M); expect to dose first BB-301 patient in 2H2023 with interim data in 12 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Benitec Biopharma Inc. reported financial results for the fiscal year ended June 30, 2023.

Period: the fiscal year ended June 30, 2023
Result: reported results

Exact text from the filing

On September 21, 2023, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal year ended June 30, 2023.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-239127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.